Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company, has reported continued progress on its proprietary AI platform and robotics integration as it nears initial commercial deployment. The company has integrated approximately 28 million scientific abstracts into its PDAOAI platform and combined it with robotics developed alongside TechForce Robotics, enabling real-time, automated workflows designed to improve efficiency and support compliance in pharmaceutical development and manufacturing.
This advancement is significant for the pharmaceutical industry, where AI and robotics are increasingly leveraged to accelerate drug discovery, reduce costs, and enhance regulatory compliance. By automating workflows, Oncotelic aims to streamline processes that traditionally require extensive manual effort, potentially reducing time-to-market for new therapies and improving data accuracy. The integration of a vast repository of scientific abstracts allows the platform to draw insights from a broad knowledge base, supporting research, biomarker discovery, and regulatory processes.
The PDAOAI platform is a key asset for Oncotelic, which focuses on oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company's CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents, contributing to a robust portfolio of inventions. Beyond its internal pipeline, Oncotelic licenses and co-develops drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates.
The move toward commercial deployment of its AI and robotics platform could position Oncotelic as a leader in technology-driven pharmaceutical development. For industry leaders, this development underscores the growing importance of AI and automation in biotech, potentially influencing investment decisions and strategic partnerships. The ability to integrate vast datasets with robotics for real-time, compliant workflows may set a new standard for efficiency in drug manufacturing and research.
As Oncotelic continues to progress, the impact on the biotechnology sector could be substantial, particularly for companies seeking to adopt similar technologies to remain competitive. The company's focus on rare and difficult-to-treat cancers also highlights the potential for AI to accelerate development of therapies for underserved patient populations. For more information, visit the company’s newsroom at https://ibn.fm/OTLC.
The full press release can be accessed at https://ibn.fm/2uitp.
